COMPANY PROFILE

Stemline Therapeutics

Stemline Therapeutics, Inc.

New York City, United StatesFounded 2003Biotech & Life Sciences

Valuation $677M Market cap · 2020

Revenue $43M Latest reported FY

About Stemline Therapeutics

Stemline Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and delivering transformative therapies for oncology patients. The company focuses on creating a broad pipeline of innovative treatments aimed at improving the lives of individuals battling cancer. Stemline serves patients, healthcare providers, and the broader medical community, operating primarily in the oncology market. The business model revolves around extensive research and development, clinical trials, and the commercialization of its proprietary therapies. Revenue is generated through the sale of these therapies, partnerships, and licensing agreements. Stemline leverages its scientific leadership and commercial expertise to bring cutting-edge treatments to market, addressing unmet medical needs in cancer care.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2003
Headquarters: New York City, United States
Listing: IPO 2013
Employees: 460
Open positions: 56
Dealroom signal: 27.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Sep 2011
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	May 2020	$677M	$677M	Menarini	↗
POST IPO EQUITYOther financing	Aug 2019	$88M	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	R&D
2026	$43M	0%	$50M
2025	$43M	0%	$50M
2024	$43M	0%	$50M
2023	$43M	0%	$50M
2022	$43M	0%
2021	$43M	0%
2020	$43M	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Stemline Therapeutics website traffic

Latest recorded traffic for Stemline Therapeutics is 6.1K monthly website visits, up 22% over the last three months. Stemline Therapeutics's team grew 0% over the past year.

Latest monthly visits6.1K 3-month web change+22% 1-year team growth0%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Oncology Territory Manager, Solid Tumor (Chicago North)Chicago, IL · Other · Sep 5, 2026 Clinical Trial LeadNew York City, New York, United States · Other · Sep 4, 2026 Senior Clinical Scientist, Solid Tumor (Director/Senior Director)New York City, New York, United States · Other · Sep 3, 2026 Key Account ManagerNew York City, New York, United States · Sales · Sep 3, 2026 Manager/Senior Manager, IT AI Product OwnerNew York, United States · Other · Aug 31, 2026 Oncology Territory Manager, Solid Tumor (Birmingham, AL)New York City, New York, United States · Other · Aug 30, 2026 Director of AccountingNew York, United States · Accounting · Aug 28, 2026 Oncology Territory Manager, Solid Tumor (Long Island, NY)New York, United States · Other · Aug 28, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioviva-scienceGene therapy and R&D company that targets cellular aging by developing new gene therapies to regenerate cells, muscles, and organs	United States	Operational	4	$250K	—
UDUniversal Medical Imaging DiagnosticOffers a holistic alternative and complementary approach to overall health that uses non-invasive, non-radioactive and painless imaging of the whole body	Los Angeles, United States	Operational
NHNavinata HealthNavinata Health is conveniently educating today's busy Physicians about innovative life-saving Therapies	Princeton, United States	Operational
PAPrecision Health AIPrecision Health AI is platform tech company that combines modern AI technology with best in class oncology data	New York City, United States	Operational
STSkyhawk TherapeuticsA drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression	Waltham, United States	Operational
OTOrbus TherapeuticsOrbus Therapeutics is dedicated to developing products that treat rare diseases	Palo Alto, United States	Operational
TBTeraFold BiologicsTeraFold Biologics is developing an integrated computational platform for discovery, modeling, and pre-clinical validation of alternative	San Francisco, United States	Operational
HBHarbour BioMedHarbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer	Cambridge, United States	Operational